Pentamidine intravenous

Drug Profile

Pentamidine intravenous

Alternative Names: OCZ 103 OS; Pentamidine bis (2-hydroxyethanesulfonate); Pentamidine isethionate

Latest Information Update: 16 Jun 2015

Price : $50

At a glance

  • Originator Unknown
  • Developer Oncozyme Pharma
  • Class Antifungals; Antineoplastics; Antiprotozoals; Benzamidines; Sulfonic acids
  • Mechanism of Action Endoexonuclease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 28 Jun 2013 Oncozyme Pharma completes a phase IIa trial for Non-small cell lung cancer (first-line combination therapy, late-stage disease) in Poland (EudraCT2012-001812-50)
  • 01 May 2013 Oncozyme Pharma completes enrolment in its phase IIa trial for Non-small cell lung cancer (first-line combination therapy, late-stage disease) in Poland (EudraCT2012-001812-50)
  • 18 Sep 2012 Phase-II clinical trials in Non-small cell lung cancer (first-line combination therapy, late-stage disease) in Poland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top